Adaptimmune Therapeutics plc
ADAPY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.58M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.58 Million |
|---|---|
| Enterprise Value | $45.41 Million |
| Earnings per Share | $-0.3 |
| Beta | 0.75 |
| Outstanding Shares | 264,087,145 |
Return
| Return on Equity | 239.23% |
|---|---|
| Return on Assets | -129.95% |
| Return on Invested Capital | -202.67% |
Valuation & Multiples
| P/E Ratio | -0.1 |
|---|---|
| PEG | 0.07 |
| Price to Sales | - |
| Price to Book Ratio | -0.03 |
| Enterprise Value to Revenue | 0.7 |
| Enterprise Value to EBIT | -0.28 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.41 |
| Debt to Equity | -0.9 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$20.63 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$22.86 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Adaptimmune Therapeutics Plc
272 employees
CEO: Christopher James Hill
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (a...